Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Gene therapy with lentiviral vectors targeting transgene expression to hepatocytes provides stable reconstitution of clotting activity in dogs with hemophilia B and does not show genotoxicity in tumor-prone mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [79]
Experimental — accuracy not yet measuredIn the citing paper
“Although AAV efforts predominate, lentiviral vectors for either systemic infusion157,158 or ex vivo transduction of hematopoietic stem cells159, 160, 161 or induced pluripotent stem cells162 are being pursued preclinically or as a phase I clinical trial.156”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Self-citationHepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777 · cited 1×
“CCl4 administration results in waves of hepatocytes necrosis and regeneration that cause liver damage (41).”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180 · cited 5×
“We produced three large-scale batches of lentiviral vectors according to a manufacturing process previously developed for clinical-grade lentiviral vectors (19, 20).”
BackgroundMethodSelf-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025 · cited 4×
“The vector batches were produced by using a large-scale validated process (19, 20) and following pre-GMP guidelines.”
BackgroundMethodSelf-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“However, there are still important hurdles to overcome before this gene therapy can be applied to the majority of severely affected patients (9).”
Background
Cited by
Items 101–158 of 158
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
Self-citationIntraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice
Joo, J. H., Wang, X., Singh, S., Chen, C., Li, C., Adair, J. E., Kiem, H., Rawlings, D. J., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008079 · Cited by 11
Minno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 12
Peres, C., Sellitto, C., Nardin, C., Putti, S., Orsini, T., Pietro, C. D., Marazziti, D., Vitiello, A., Calistri, A., Rigamonti, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104453 · Cited by 14
Tridgett, M., Mulet, M., Johny, S. P., Ababi, M., Raghunath, M., Fustinoni, C., Galabova, B., Fernández-Díaz, C., Mikalajūnaitė, I., Tomás, H. A., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101315 · Cited by 13
Kaiser, R. A., Nicolas, C. T., Allen, K. L., Chilton, J. A., Du, Z., Hickey, R., & Lillegard, J. B. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.249 · Cited by 11
Aronovich, E. L., Hyland, K. A., Hall, B. C., Bell, J. B., Olson, E. R., Urness, M., Hunter, D. W., Ellinwood, N. M., McIvor, R. S., & Hackett, P. B. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.004 · Cited by 14
Synthetic Circuit-Driven Expression of Heterologous Enzymes for Disease Detection
He, J., Nissim, L., Soleimany, A. P., Binder-Nissim, A., Fleming, H. E., Lu, T. K., & Bhatia, S. N. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00133 · Cited by 9
“Several such approaches convert the activity of enzymes, such as proteases, involved in disease progression into an imaging or bio fl uid-based detection readout.”
Hemophilia Gene Therapy: New Development from Bench to Bed Side
Guo, X., Chung, T., Qin, Y., Zheng, J., Zheng, H., Sheng, L., Wynn, T., & Chang, L. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190924121836 · Cited by 10
Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering
Milani, M., Starinieri, F., Beretta, S., Monti, M., Canepari, C., Marabotti, F., Zambrano, S., Mazza, D., Fabiano, A., Simoni, C., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.018 · Cited by 13
Self-citationGene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 14
“Particularly, ABEs were used to treat 4 NHPs (Musunuru et al., 2021). mRNA encoding for ABEs and guide RNA (gRNA) targeting PCSK9 were packaged in an LNP and injected systemically by a one-time treatment.”
BackgroundInfluentialSelf-citationTang, Q., Hu, Z., Zhao, J., Zhou, T., Tang, S., Wang, P., Xiao, R., Chen, Y., Wu, L., Zhou, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109013 · Cited by 8
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients.
Khalilian, S., Motovali-Bashi, M., & Rezaie, H. (2020) · PubMed Central · doi:10.22088/ijmcm.bums.9.1.33 · Cited by 8
Kao, Y., Yen, C., Fan, H., Chen, J., Chen, M., Lan, Y., Yang, S., & Chen, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216411 · Cited by 6
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang, X., Fu, R. Y., Li, C., Chen, C., Firrman, J., Konkle, B. A., Zhang, J., Li, L., Xiao, W., Poncz, M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002479 · Cited by 10
Canestrale, A. R., Kholia, S., Dimuccio, V., & Sanchez, M. B. H. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm16010001 · Cited by 7
“Work from Cantore et al. and Canepari et al. showed durable liver transduction using integrating LVs platforms that bypass pre-existing immunity and maintain expression throughout hepatocyte turnover [142,143].”
New technologies in gene therapy for inducing immune tolerance in hemophilia A
Borsotti, C., & Follenzi, A. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1539667 · Cited by 5
Viral vectors engineered for gene therapy
Lundstrom, K. H. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.005 · Cited by 5
Moving Forward Toward a Cure for Hemophilia B
VandenDriessche, T., & Chuah, M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.56 · Cited by 5
Self-citationÇelik, B., Rintz, E., Khan, S. A., Leal, A. F., Nidhi, F., & Tomatsu, S. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101514 · Cited by 5
Gene Therapy for Inherited Liver Disease: To Add or to Edit
Chen, Y., van Til, N. P., & Bosma, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312514 · Cited by 4
Milani, M., Starinieri, F., Fabiano, A., Beretta, S., Plati, T., Canepari, C., Biffi, M., Russo, F., Berno, V., Norata, R., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115341 · Cited by 4
Self-citationCD14 positive cells accelerate hematopoietic stem cell engraftment
Pievani, A., Granata, V., Desantis, G., Antolini, L., Ornaghi, S., Galleu, A., Biondi, A., Gentner, B., Dazzi, F., & Serafini, M. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01662-1 · Cited by 4
Micromanaging Tolerance in Hemophilia A Gene Therapy
Jobson, J., & Brown, B. D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.001 · Cited by 4
Sawczuk, I. S., & Wechsler, M. E. (1985) · PubMed Central · Cited by 5
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3
Genetic Therapy in Veterinary Medicine
Zakirova, E. Y., Malanyeva, A. G., Rutland, C. S., & Аймалетдинов, А. М. (2022) · BioNanoScience · doi:10.1007/s12668-022-00986-y · Cited by 3
Rewriting the script: gene therapy and genome editing for von Willebrand Disease
Barraclough, A., Bär, I., van Duijl, T. T., Fijnvandraat, K., Eikenboom, J. C. J., Leebeek, F. W. G., Bierings, R., Voorberg, J., & Trasanidou, D. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1620438 · Cited by 4
“LV delivery was also explored in a canine model to treat hemophilia B with surprisingly positive results and no long-term toxicity in the animal model (Cantore et al., 2015).”
Insulin Gene Therapy for Type 1 Diabetes Mellitus: Unique Challenges Require Innovative Solutions
Handorf, A. M., Sollinger, H. W., & Alam, T. (2016) · InTech eBooks · doi:10.5772/62657 · Cited by 7
Kandina, D. A., Velizhanina, M. E., Sopova, J. V., & Леонова, Е. И. (2025) · Cell and Tissue Biology · doi:10.1134/s1990519x25600024 · Cited by 2
“However, their use in human therapy is limited due to risks such as genomic integration, which may lead to mutations, potential malignancies, or other adverse effects (Cantore et al., 2015).”
Artemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
“ET promoter was used in lentiviral-based preclinical studies of hemophilia B therapy in mice and dogs, which resulted in stable but weak expression level of cFIX [293].”
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development
Fang, E., He, G., Chang, Y., He, Q., Chen, P., & Hu, K. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01472-y · Cited by 8
Collagen Type II-Targeting Lentiviral Gene Therapy for Mucopolysaccharidosis IVA
Çelik, B., Saikia, S., Khan, S., Musini, K. S., & Tomatsu, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb48010042 · Cited by 1
“Previous studies have shown a reduction in viral titer due to modifications of the viral envelope and complications with gene cassettes [36].”
Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
Cozmescu, A. C., Nazari, M., Touramanidou, L., Gurung, S., Perocheau, D. P. B., Sebire, N. J., Hu, Y., Goldsworthy, S., Burden, J. J., Khalil, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73631-x · Cited by 3
“Oursafety datafortheliver-speci fi c lentiviral vector aligns with previous studies that have used lentiviral vectors to target the liver, which demonstrated its safety and ef fi cacy in canine models of haemophilia B 27 , as well as in murine and non-human primate models of haemophilia A 28 .”
Biotechnological Approaches to Discovery of Drugs for Veterinary Use
Abdelkarim, O. F., Rehman, S. U., Samad, A., Khan, I. U., Akram, M. W., Sayeed, M. A., Tchaptchet Yimga, F. G., Arshad, M. A., Rashid, A., & Basit, A. (2024) · Futuristic Biotechnology · doi:10.54393/fbt.v4i04.150 · Cited by 1
Gender difference in pre-clinical liver-directed gene therapy with lentiviral vectors
Guzman, E., Khoo, C. P., O’Connor, D., Devarajan, G., Iqball, S., Souberbielle, B. E., Mitrophanous, K. A., & Lad, Y. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10422 · Cited by 1
“Duplex qPCR (QuantStudio 7, Thermo ABI) was performed on the liver-extracted DNA to obtain LVV integrated VCN per cell as described before [7] using the transferrin receptor protein 1 ( tfrc ) as a housekeeping gene.”
Handorf, A. M., Hw, S., & Alam, T. (2017) · Journal of Diabetology and Endocrinology · doi:10.14312/2398-0281.2017-1 · Cited by 1
Lundstrom, K. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00049-4 · Cited by 1
Cantore, A., Starinieri, F., Milani, M., Beretta, S., Canepari, C., Fabiano, A., Simoni, C., Cammarota, E., Volpin, M., Bortolussi, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3138832/v1 · Cited by 1
Self-citationGene Therapy for Bleeding Disorders
Monahan, P. E., & Abajas, Y. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_29
Construção e análise funcional de vetores lentivirais de interesse biotecnológico
Vedoveli, N. C. P. S. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2016.tde-26082016-152814 · Cited by 1
Hemophilia Gene Therapy; Clinical and Molecular Aspects
Zaree, M., Sabzevary, M., Ahmadi, A., Ramezanzadeh, M., & Bereshneh, A. H. (2017) · Journal of Human Genetics and Genomics · doi:10.5812/jhgg.80764
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Assaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Milani, M., Starinieri, F., Beretta, S., Fabiano, A., Plati, T., Canepari, C., Biffi, M., Russo, F., Norata, R., Sanvito, F., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4452657
Self-citationAplicación e impacto de la transgénesis animal
Beltran, G. J. A., Angarita, A. M. M., Gallego, A. M., León, L. B., & Lopera-Vásquez, R. (2023) · Journal of Agricultural Sciences Research (2764-0973) · doi:10.22533/at.ed.9733102313073
“…Crispo et al. (2015) 2017 Uso de lentivirales para la expresión de un transgén del factor IX en hepatocitos de caninos afectados por hemofilia B Cantore et al. (2015) 2020 Patogénesis del SARS-COV-2 en ratones transgénicos que expresan la enzima convertidora de angiotensina 2 Jiang et al.…”
BackgroundMoeini, P., & González‐Aseguinolaza, G. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_173
Canepari, C., Milani, M., Degl’Innocenti, S., Monti, M., Volpin, M., Starinieri, F., Cavallo, M., Fabiano, A., Biffi, M., Longo, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.036 · Cited by 2
Self-citationBalancing Promise and Peril: Hemophilia Gene Therapy Insights
Akula, S., Borroni, E., Cottonaro, A., Follenzi, A., & Merlin, S. (2026) · IUBMB Life · doi:10.1002/iub.70087
“In preclinical models, these vectors have demonstrated stable and sustained long-term expression of the therapeutic protein directly within the liver [64–66].”
Healing the Liver: Cell and Gene Therapies for Inherited and Acquired Diseases
Borroni, E., Cirsmaru, R. A., Follenzi, A., & Merlin, S. (2026) · Livers · doi:10.3390/livers6020018
New therapeutic strategies for the treatment of β-hemoglobinopathies
Weber, L. (2018) · theses.fr (ABES) · doi:10.70675/09314463zdfd1z46b4z9c0cz32c6c2c5ccc2
Développement d'un traitement de thérapie génique pour la glycogénose de type III
Vidal, P. (2018) · theses.fr (ABES) · doi:10.70675/5e174471z66d8z44dbza2edz3adc480b1f41
Gene Therapy in Bleeding Disorders
Reiss, U. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_24
Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice
Bell, R. V., Faulkner, N., Sinadinos, A., Meng, C., Castells, E., Viegas, M. A., Hyde, S. C., Gill, D. R., Alton, E. W. F. W., & Uta Griesenbach, D. (2026) · Gene Therapy · doi:10.1038/s41434-026-00623-3
Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery
Keating, A. L., Carlisle, R. C., Mitrophanous, K. A., Seymour, L. W., & Fisher, K. D. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201856
Metadata
- Authors
- Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., Raymer, R., Merricks, E., Bellintani, F., Martin, S., Doglioni, C., D’Angelo, A., VandenDriessche, T., Chuah, M. K., Schmidt, M., Nichols, T., Montini, E., & Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- German Cancer Research Center (DE)
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- University of North Carolina at Chapel Hill (US)
- MolMed (Italy) (IT)
- Genethon (France) (FR)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Cantore, Alessio
- Ranzani, Marco
- Nichols, Timothy
- Montini, Eugenio
- Naldini, Luigi
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-04
- Volume
- 7
- Issue
- 277
- Pages
- 277ra28-277ra28
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5669486
- OpenAlex
- W2099852853
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 12 · 2023: 15 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 19 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 7
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- NIH (HL063098)
- European Union Seventh Framework Programme (222878-PERSIST)
- European Research Council Advanced
- Telethon (D3)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, lentiviral vectors, liver-directed gene therapy, canine model, insertional mutagenesis, genotoxicity, hepatocytes, coagulation factor IX, large animal model
- MeSH terms
- Animals, Blood Coagulation, Hemophilia B, Disease Models, Animal, Dogs, Female, Genetic Vectors, Liver, Mice, Inbred C57BL, Mutagens, Time Factors, Transduction, Genetic, Genetic Therapy, Lentivirus, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.